Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia

Elderly patients with acute myeloid leukemia (AML) have been found to clinically benefit from the combination of azacitidine (AZA) and venetoclax (VEN), although the safety and efficacy of the treatment in extremely elderly patients (age >85 years) have not been fully established. An 88-year-old...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujino, Keita, Ureshino, Hiroshi, Yoshida, Tetsumi, Ichinohe, Tatsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Hematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290478/
https://www.ncbi.nlm.nih.gov/pubmed/37362503
http://dx.doi.org/10.7759/cureus.39481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290478/
https://www.ncbi.nlm.nih.gov/pubmed/37362503
http://dx.doi.org/10.7759/cureus.39481

Ejemplares similares